Navigation Links
BDSI Announces Positive Key Secondary Efficacy Endpoint Results for,Bema Fentanyl

MORRISVILLE, N.C.--(BUSINESS WIRE)--May 14, 2007 - BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced additional statistically significant results with BEMA Fentanyl in cancer patients with breakthrough pain in its Phase III efficacy clinical trial for the product.

Results were based on the company's continuing analysis of the secondary efficacy endpoints from the study. A key secondary endpoint was the SPID 15 (Summary of Pain Intensity Difference at 15 minutes), a measure of the speed of onset of the medication. The study data indicate that the SPID 15 was significantly higher on BEMA(TM) Fentanyl than with placebo.

On April 25, 2007, BDSI announced statistically significant results of its primary efficacy endpoint for the BEMA(TM) Fentanyl Phase III trial, SPID 30 (Summary of Pain Intensity Difference at 30 minutes). BEMA(TM) Fentanyl consists of a small, dissolvable polymer disc, formulated with the opioid narcotic fentanyl, for application to the buccal (inner lining of cheek) membranes. Upon administration, BEMA(TM) Fentanyl is designed to deliver a rapid, reliable dose of drug across the mucous membranes.

In addition to the SPID 15 endpoint, the company also reported that the overall global analysis of the treatment, which represents each patient's overall satisfaction with the product, was also found to be statistically superior to the placebo.

Dr. Andrew Finn, BDSI's Executive Vice President of Product Development, stated: "We are very pleased with the outcome of the results from our current secondary endpoint analyses from our Phase III efficacy study which, as previously announced, we plan to present along with other efficacy and safety data at an upcoming scientific forum to be determined. We are particularly pleased to see that the onset of analgesia with BEMA(TM) Fentanyl is rapid, since a quick onset of action is one of the anticipated features of delivering fe
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:7/11/2014)... , July 11, 2014 Neurelis, Inc. ("Neurelis") ... to end the option held by Biotie to purchase ... development of NRL-1 (intranasal diazepam) for pediatric and adult ... Over the past year, Biotie has advanced the development ... for the pivotal clinical work required for NDA submission ...
(Date:7/10/2014)... NEWPORT NEWS, Virginia , 11. ... führender Hersteller von Kameras für die ... Brust (MBI/BSGI), hat heute die CE-Zulassung ... Mit dem CE-Zeichen kann Dilon das ... seinen Vertriebsbereich auf den Großteil der ...
(Date:7/10/2014)... Calif. , July 10, 2014  Breg, ... and services, has launched the FreeRunner™ knee brace ... who suffer from patella mal-tracking return to active ... differently than other braces, providing support when patients ... normally when they don,t. Patellofemoral issues ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... 14, 2012  The Consumer Healthcare Products Association (CHPA) ... into law House Bill 2263—anti-meth legislation authored by ... 23rd state to adopt real-time, stop-sale technology known ... The proven system—in a process similar ...
... SCHLIEREN-ZURICH, Switzerland, May 14, 2012 The ALS ... it has entered into collaboration with Neurotune ... Neuron or Lou Gehrig,s disease). (Photo: ... "Maintaining the health of motor neurons ...
Cached Medicine Technology:CHPA Applauds Arizona's Adoption Of HB 2263 2The ALS Therapy Development Institute Partners with Neurotune to Investigate Potential Treatments for Motor Neuron Disease 2The ALS Therapy Development Institute Partners with Neurotune to Investigate Potential Treatments for Motor Neuron Disease 3
(Date:7/13/2014)... According to a new market research ... Component (processor, GPU, DSP, connectivity), Technology Node (45nm-5nm), ... - Forecast and Analysis to 2014-2020", published by ... Market is expected to reach $61.70 Billion by ... 2014 to 2020. , Browse 71 market data ...
(Date:7/13/2014)... Serena Gordon HealthDay ... A new type of sensor for people with diabetes ... using saliva instead of blood, researchers report. Scientists at ... tested it using artificial saliva. It uses light, metal and ... sugar. "Everybody knows that diabetics have to prick their ...
(Date:7/13/2014)... 13, 2014 The federal court overseeing ... filed against Johnson & Johnson’s Ethicon, Inc. is ... is expected to get underway next month. According to ... District Court, Southern District of West Virginia on July ... August 7, 2014 at 3:00 p.m. July selection is ...
(Date:7/13/2014)... Recently, MyDressCity.com, one of the most popular ... has released its new range of elegant Quinceanera ... available at discounted prices. Worldwide clients can enjoy this ... the company’s online shop, there are plenty of beautiful ... with great materials. MyDressCity.com’s hot items are prom gowns, ...
(Date:7/13/2014)... A noninvasive optical imaging device developed at ... later occur in the brain and are a ... results from investigators conducting a clinical trial in ... July 15 in an oral presentation at the ... They also were invited by conference organizers to ...
Breaking Medicine News(10 mins):Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3
... Scientists at Duke University Medical Center may have solved the ... they say may renew interest in gold salts as a ... first used injections of gold salts in the early 1900s ... But treatment came at a high cost: The shots ...
... 22 With health,facilities across the country struggling ... Veterans Affairs (VA) are demonstrating leadership by,collaborating in ... the federal healthcare supply chain. Through the innovative ... and expanding their ongoing,initiatives to both standardize and ...
... of virus in the blood of an HIV-infected personhas ... quickly someone infected with HIV infection progresses to AIDS. ... work that suggests that several other factors in addition ... , Researchers led by Sunil Ahuja, M.D., of the ...
... , , MONDAY, Oct. 22 (HealthDay News) -- If you,re sneaking ... a common device can determine whether someone is a smoker. ... to ferret out people who hide a cigarette habit, ... patients what smoking is doing to their bodies, he added. ...
... vascular surgery, picks up size 7 crochet hooks from a fabric ... in a new technique he has developed to treat varicose veins. ... procedure, called light-assisted stab phlebectomy, or LASP, appear in a study ... , More than 250 patients at UCLA have ...
... Information,Systems (Nasdaq: MEDW ) announced today that ... licensed Mediware,s HCLL(TM) Transfusion,Management software system, which provides ... transfusion errors, improve patient,safety and maximize operational efficiency. ... is based in Dallas, Texas, and,through its subsidiaries, ...
Cached Medicine News:Health News:Scientists discover how gold eases pain of arthritis 2Health News:DoD and VA to Reduce Healthcare Supply Chain Costs 2Health News:DoD and VA to Reduce Healthcare Supply Chain Costs 3Health News:DoD and VA to Reduce Healthcare Supply Chain Costs 4Health News:Blood Test Catches Secret Smokers 2Health News:Blood Test Catches Secret Smokers 3Health News:UCLA doctor develops new technique to treat varicose veins 2Health News:UCLA doctor develops new technique to treat varicose veins 3Health News:Mediware's Transfusion Management Software Adopted by Four Additional Tenet Hospitals 2Health News:Mediware's Transfusion Management Software Adopted by Four Additional Tenet Hospitals 3
Colloidal Gold Conjugated, Goat anti-human IgM (Mu Chain) - 50 OD...
Colloidal Gold Conjugated, Goat anti-human IgA (Alpha Chain) - 50 OD...
Polyester ribbon impregnated with conjugated Protein A - .50 OD per sq. cm....
Polyester ribbons (3) impregnated with different OD values of conjugated Protein G...
Medicine Products: